Rituximab is associated with improved survival for aggressive B cell CNS lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab is associated with improved survival for aggressive B cell CNS lymphoma

Published:2013-03-15 Issue:8 Volume:15 Page:1068-1073
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:Neuro-Oncology

Author:

Gregory G.,Arumugaswamy A.,Leung T.,Chan K.-L.,Abikhair M.,Tam C.,Bajel A.,Cher L.,Grigg A.,Ritchie D.,Opat S.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/15/8/1068/4035222/not032.pdf

Reference26 articles.

1. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The massachusetts general hospital experience 1958-1989

2. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy

3. Treatment for Primary CNS Lymphoma: The Next Step

4. Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10

5. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020;Neuro-Oncology;2024-06-25

3. Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance;eJHaem;2024-06-21

4. Adult Lymphomas;Tata Memorial Centre Textbook of Oncology;2024

5. Diagnostic Value of sLR11 and sIL-2R in the Cerebrospinal Fluid for Malignant Central Nervous System Lymphoma;Internal Medicine;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3